Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Portrazza(Necitumumab)耐昔妥珠单抗

Necitumumab (INN: Necitumumab) is a recombinant human IgG1 monoclonal antibody used as an anti-tumor drug and produced by Eli Lilly and Company. It binds to the epidermal growth factor receptor (EGFR). The U.S. Food and Drug Administration approves nesituzumab (brand name Portrazza), along with gemcitabine and cisplatin, for the treatment of untreated metastatic squamous non-small cell lung cancer (NSCLC).

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.